Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Allergy Therapeutics PLC on Monday said it appointed Martin Hopcroft as interim chief financial officer, as Nick Wykeman will step down at the end of November.
Allergy Therapeutics is a West Sussex-based commercial biotechnology company.
Hopcroft was previously CFO at Novasep SA, a supplier of pharmaceuticals and biopharmaceuticals. During his tenure, Novasep won a contract with AstraZeneca to support the production of the active substance of its adenovirus vector-based Covid-19 vaccine.
Hopcroft also served as CFO at formerly listed Cambian Group PLC, a provider of specialist residential and educational services for children and young adults, and at Consort Medical PLC, a medical devices company.
In the role, Hopcroft will report to Chief Executive Manuel Llobet, once Wykeman steps down this month to pursue non-executive roles.
Allergy Therapeutics said it is searching for a permanent CFO.
Allergy Therapeutics shares were down 3.3% to 14.50 pence on Monday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.